Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer due in part to a lack of highly robust cytotoxic or molecular-based therapies. Recent studies investigating ligand-mediated Wnt/β-catenin signaling have highlighted its importance in pancreatic cancer initiation and progression, as well as its potential as a therapeutic target in PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest of cancers, with an overall five-year survival rate of approximately 6% (1) . PDAC is difficult to treat because it frequently presents at an advanced, non-operative stage and is highly resistant to cytotoxic or targeted molecular therapy (2) . While our understanding of the molecular and cellular basis of PDAC continues to expand, present therapeutic options remain limited and offer only modest survival benefits for most patients.
Wnt/β-catenin signaling is a critical developmental signaling pathway whose dysregulation is strongly implicated in the pathogenesis of many types of cancers (3) .
Canonical mutations in CTNNB1, APC and AXIN that lead to constitutive hyperactivation of the pathway occur only infrequently in PDAC (4, 5) . Nevertheless, perturbations in the timing, context and strength of Wnt/β-catenin signaling can promote the development and progression of PDAC (4, 5) . Ligand-mediated Wnt/β-catenin signaling is essential for pancreatic cancer initiation and progression (6) and has been linked to aggressive tumor behavior (7) . Wnt pathway activation as detected by nuclear and/or cytoplasmic accumulation of β-catenin is observed in 10-65% of pancreatic intraepithelial neoplasia (PanIN) (8, 9) , increasing with higher PanIN grade and invasive PDAC (10) . Genetic or pharmacologic inhibition of various steps in the Wnt pathway has also been shown to prevent in vitro (7, 9, 10) and in vivo tumor growth (6, (10) (11) (12) (13) , implicating Wnt signaling as therapeutic target in PDAC.
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Author Manuscript Published OnlineFirst on July 31, 2014; DOI: 10.1158/1535-7163. MCT-13-1005 Although previously plagued by poor in vivo pharmacokinetics, several novel Wnt/β-catenin inhibitors have demonstrable in vivo activity and are now in various stages of preclinical or early clinical development. These include naturally occurring compounds, small molecule inhibitors, blocking antibodies and peptide antagonists (5, 14, 15) . ICG-001 was identified in a screen of small molecules that inhibited Wnt/β-catenin transcriptional activity in a colorectal cancer cell line (16) . ICG-001 selectively blocks the interaction of β-catenin with its transcriptional co-activator cyclic-AMP-responseelement-binding protein (CBP) without disrupting β-catenin interaction with highly homologous p300. One significant effect ascribed to ICG-001 and its disruption of Wnt/β-catenin transcription is decreased expression of the apoptosis inhibitor BIRC5 (aka survivin protein), which leads to activation of caspase-3/7-mediated apoptosis (16) (17) (18) (19) .
ICG-001 was first shown to slow colorectal cancer xenograft growth and intestinal polyp formation in the Apc min mouse model (16) and has been subsequently shown to have in vivo efficacy in other Wnt-driven disease models, including rodent models of pulmonary fibrosis (20) , renal interstitial fibrosis (21) , acute lymphoblastic leukemia (22) , chronic myocardial infarction (23) , dermal fibrosis (24) and salivary tumorigenesis (25) . The ICG-001-derived compound PRI-724 is now under investigation as a Wnt inhibitor in early phase clinical trials for advanced solid tumors (NCT01302405) and myeloid malignancies (NCT01606579) (26) .
Given the importance of Wnt signaling in pancreatic carcinogenesis, we have now explored therapeutic potential and mechanism of action of ICG-001 in PDAC. ICG-001 significantly inhibited in vitro and in vivo PDAC growth by inducing G1 cell cycle arrest 
Materials and Methods

Cell Lines and Reagents
All cell lines were cultured as previously described (7) . AsPC-1, MiaPaCa-2 and PANC-1 were obtained in 2005 from the American Type Culture Collection (Rockville, MD).
L3.6pl was obtained in 2010 from Hong Wu (UCLA). The cell lines have not been subsequently authenticated since receipt. ICG-001 was purchased from Selleck Chem and gemcitabine was kindly provided by Timothy Donahue (UCLA). Wnt3a and L-cell conditioned media were prepared as previously described (7) .
Cell growth, proliferation and apoptosis assays
MTT cell viability assays (ATCC) were carried out per manufacturer's instructions at initial plating of 5,000 (AsPC-1 and L3.6pl) or 3,000 (MiaPaCa-2 and PANC-1) cells per well in 96-well plates. Soft agar assays were performed as previously described (7) in 48-well format. Media and drug were replenished once every 3-4 days. For cell cycle analysis, treated cells were stained using hypotonic DNA staining buffer: 0.1mg/ml propidium iodide (Calbiochem), 20μg/ml RNaseA, 1mg/ml sodium citrate and 0.3% Triton X-100. Flow cytometry analysis was performed in the UCLA Flow Cytometry Core using a Becton Dickinson FACSCalibur cytometer and using ModFit LT v3.1 software. Annexin V-PI flow cytometry analysis was performed with Cellquest v3.3 software using an Annexin V FITC Apoptosis Detection Kit (BD Biosciences). AsPC-1 cells suspended in 50% Matrigel (BD Biosciences)/RPMI into surgically-exposed pancreatic tails of 6-week old female athymic nude mice (Charles River) as previously described (27) . Intraperitoneal drug injections were begun 10 days after tumor cell injections in animals randomized to four treatment arms: vehicle alone (20% PEG300, 5% solutol, 3.75% dextrose, 1% DMSO in PBS) (n=12), ICG-001 (5 mg/kg 6 days/week) (n=12), gemcitabine (25 mg/kg 2 days/week) (n=11) or ICG-001 + gemcitabine (n=12). Treatment was for 8 weeks and then discontinued for the remainder of the study (up to 120 days post-surgery). Animals were monitored daily and sacrificed per institutional guidelines when reaching either a Body Conditioning Score of 2 (28) or palpable tumor of 1.5 cm in diameter. Full necropsy was performed at the time of death with snap frozen and formalin-fixed tissue sections taken of primary and metastatic tumors, as well as normal spleen, lung, liver, small and large intestine. Histologic analysis was performed with H&E stained sections by a practicing surgical pathologist (DWD) blinded to treatment arms. Ten random high power fields per tumor were analyzed for mitotic counts. A previously described dissemination score awarding points based on tumor infiltration and metastasis (29) was used to quantify tumor spread.
Orthotopic Xenograft Tumor Assay
Wnt reporter assays
Dual luciferase assays (Promega) were performed as previously described (7) 
Real-time PCR
RNA extraction, cDNA synthesis and SYBR Green-based quantitative PCR were performed as previously described(7) using primers listed in Supplemental Table 1 .
Western Blots and Immunoprecipitation
Western blots were performed as previously described (7) using antibodies specific for β- AsPC-1 cells (70% confluency) were crosslinked with formalin. Chromatin immunoprecipitation (ChIP) was performed using the Pierce Agarose ChIP Kit (Thermo Scientific) on chromatin digested with 2U micrococcal nuclease. Digested chromatin extracts were precleared with 20 ug agarose beads and incubated overnight with beads pre-bound with either 5 μg IgG control or CBP antibody (Abcam, ab46540 and ab2832, respectively) blocked with 1μg fish sperm DNA. PCR was performed using primers (Supplemental Table 1 ) covering gene regulatory regions for CDKN1A (-231 to -117 relative to transcriptional start site, TSS), SKP2 (+1772 to +1870 relative to TSS) and CDC25A (-31 to -310 relative to TSS). P<0.01 at 6 hours or >2-fold change and P<0.01 at 24 hours). β-catenin-regulated genes were determined by comparative analysis of CTNNB1 versus control siRNA tranfection (selection criteria ≥1.33-fold change and >50 absolute change). Functional enrichment was examined using default parameters in the web-based Database for Annotation, Visualization and Integrated Discovery (DAVID, v6.7) (http://david.abcc.ncifcrf.gov) (32) . Analysis was limited to the GO biological process FAT (GOTERM_BP_FAT) category terms and ranked on P-values after removal of categories with less than 6 annotated genes.
Gene expression microarray and data analysis
Statistics
Student t tests were used to compare continuous variables. The Cox proportional hazard model was used to estimate hazard ratios between treatment groups. The assumption of proportionality was assessed both by visual inspection of Kaplan-Meier survival curves and formal analysis of Schoenfeld residuals (p.val=0.13). Kaplan-Meier survival curves and log rank tests were performed using GraphPad Prism. Table 2 ). Using a previously described scoring system that awards points based on tumor infiltration and metastasis (29) 
ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling
We next explored mechanisms underpinning ICG-001 pancreatic growth inhibitory effects. As previously shown in colorectal cancer (16) 
ICG-001, a concentration for which only AsPC-1 showed appreciable inhibition of Wnt transcriptional activity.
If ICG-001 exerts anti-proliferative effects by inhibiting β-catenin-mediated transcription, this effect should be phenocopied by knockdown of β-catenin expression. However, siRNA-mediated CTNNB1 gene knockdown failed to induce G1 arrest in AsPC-1 cells, whereas parallel ICG-001 treatment did induce significant G1 arrest ( Figure 4D ).
Furthermore, while exogenous Wnt3A ligand treatment fully rescued ICG-001 inhibition of Wnt reporter activity in the cell lines, it had no effect on ICG-001-mediated G1 cell cycle arrest (Supplemental Figure 3) . Altogether, these data indicate that ICG-001 mediates growth arrest in PDAC cell lines through mechanisms discrete from its action as an inhibitor of Wnt signaling.
ICG-001 inhibits the expression of genes involved in cell cycle
To explore mechanisms underlying ICG-001 inhibition cell cycle in PDAC, gene expression microarrays were performed on AsPC-1 cells after 6 and 24 hours of treatment with ICG-001. In total, 569 transcripts (419 upregulated and 150 downregulated) showed altered expression in response to ICG-001 treatment (P < 0.01; 1.67-fold change at 6 hours or 2-fold change at 24 hours; 0.2% median false discovery rate) ( Figure 5A and Supplemental Table 3 
catenin, resulting in increased p300/γ-catenin interaction and decreased BIRC5 expression (22, 44) .
ICG-001 can induce caspase-3/7-mediated apoptosis in colon cancer cells via downregulation of BIRC5 (16) . Although ICG-001 treatment inhibited survivin protein levels, there were only variable and modest effects on apoptosis in PDAC cell lines.
Rather, ICG-001 induced robust G1 cell cycle arrest, which is perhaps not unexpected given CBP/p300 histone acetyltransferase activity is essential for cell proliferation and orderly G1/S transition (45) . Several groups find Wnt/β-catenin signaling promotes cellular proliferation in PDAC(4,9) and while Wnt/β-catenin transcriptional targets MYC 
